Nymox Pharmaceutical Corporation (NYMX) Sees Large Decline in Short Interest
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) was the target of a significant decrease in short interest in October. As of October 13th, there was short interest totalling 910,562 shares, a decrease of 22.8% from the September 29th total of 1,179,164 shares. Based on an average trading volume of 80,819 shares, the short-interest ratio is presently 11.3 days. Currently, 3.0% of the shares of the company are short sold.
Separately, ValuEngine upgraded shares of Nymox Pharmaceutical Corporation from a “sell” rating to a “hold” rating in a research note on Friday, August 11th.
A number of institutional investors have recently made changes to their positions in NYMX. State Street Corp bought a new stake in Nymox Pharmaceutical Corporation in the 2nd quarter valued at about $1,323,000. TIAA CREF Investment Management LLC bought a new stake in Nymox Pharmaceutical Corporation in the 2nd quarter valued at about $329,000. Bank of New York Mellon Corp bought a new stake in Nymox Pharmaceutical Corporation in the 2nd quarter valued at about $323,000. Vanguard Group Inc. bought a new stake in Nymox Pharmaceutical Corporation in the 2nd quarter valued at about $302,000. Finally, Wedbush Securities Inc. raised its stake in Nymox Pharmaceutical Corporation by 30.6% in the 2nd quarter. Wedbush Securities Inc. now owns 234,692 shares of the biopharmaceutical company’s stock valued at $1,033,000 after acquiring an additional 55,000 shares during the period. Institutional investors and hedge funds own 5.79% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Nymox Pharmaceutical Corporation (NYMX) Sees Large Decline in Short Interest” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://theolympiareport.com/2017/11/02/nymox-pharmaceutical-corporation-nymx-sees-large-decline-in-short-interest.html.
Nymox Pharmaceutical Corporation Company Profile
Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.
Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.